July 23rd 2024
AIC100 now has a regenerative medicine advanced therapy designation from the FDA for the treatment of recurrent anaplastic thyroid cancer.
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Analysis Determines Potential Feasibility of PSMA PET Imaging for Metastatic Thyroid Cancer
January 14th 2021Gallium-68 prostate-specific membrane antigen PET imaging demonstrated the ability to detect metastatic thyroid cancer but resulted in a lower detection rate compared with 2-[18F]FDG PET for thyroid cancer lesion visualization.
Read More
Tissue TMB Shows Potential as Biomarker of Response to Pembrolizumab in Thyroid Cancer
January 12th 2021Patients with tissue tumor mutational burden-high solid tumors represent a subset of patients who could have a robust tumor response to the immune checkpoint inhibitor pembrolizumab as monotherapy, suggesting tTMB may be a novel and useful predictor of response in patients with previously treated recurrent or metastatic advanced solid tumors, including thyroid cancer.
Read More
VEGFR Targeting with Cabozantinib Achieves PFS Benefit in RAI-Refractory DTC
December 22nd 2020Cabozantinib demonstrated significant improvement in progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to 2 prior vascular endothelial growth factor receptor-targeted therapies compared with placebo, meeting the primary end point of the pivotal phase 3 COSMIC-311 clinical trial.
Read More
Multiple Studies Provide Efficacy Results for Lenvatinib in Thyroid Cancer
November 27th 2020Matthew Taylor, MD, reviewed the clinical trials supporting levantinib as a treatment option for a patient with thyroid cancer and discussed the option with a group of oncologists during a Targeted Oncology Case Base Peer Perspectives event.
Read More
Real-World Data Support Use of Multikinase Inhibitors in Differentiated Thyroid Cancer
October 20th 2020In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the findings for the global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.
Read More
ESMO Data Show Benefit of Approved Thyroid Cancer Regimens in Select Patients
October 14th 2020Across subsets of patients with thyroid cancer, an interesting collection of research was shared with oncologists during the 2020 European Society of Medical Oncology Virtual Congress, demonstrating improvement in outcomes for patients with thyroid cancers with newer and established approved regimens.
Read More
Patient-Reported Outcomes Confirm Tolerability of Selpercatinib in RET-Driven Thyroid Cancer
October 12th 2020In an interview with Targeted Oncology, Lori J. Wirth, MD, discussed the findings from an analysis of the patient-reported outcomes observed in the LIBRETTO-001 study of selpercatinib in patients with RET-driven thyroid cancers.
Read More
Larotrectinib Induces Promising Response Rate in Patients With Differentiated Thyroid Cancer
September 21st 2020Larotrectinib as treatment of patients with TRK fusion-positive thyroid cancer had rapid and durable disease control, with the highest response rates observed in the differentiated thyroid cancer population.
Read More